|4th January 2021||Sandford D Smith||511||Grant/award etc.||$19.56||$9,995.16|
|5th October 2020||Sandford D Smith||5,936||Exercise of derivative||$7.37||$43,748.32|
|5th October 2020||Sandford D Smith||5,936||Open or private sale||$30.00||$178,080.00|
|15th July 2020||Sandford D Smith||6,667||Exercise of derivative||$6.21||$41,402.07|
|15th July 2020||Sandford D Smith||6,667||Open or private sale||$29.00||$193,343.00|
|10th July 2020||Sandford D Smith||6,667||Open or private sale||$28.00||$186,676.00|
|10th July 2020||Sandford D Smith||6,667||Exercise of derivative||$6.21||$41,402.07|
|8th July 2020||Sandford D Smith||1,434||Exercise of derivative||$6.21||$8,905.14|
|8th July 2020||Sandford D Smith||1,434||Open or private sale||$27.00||$38,718.00|
|7th July 2020||Sandford D Smith||6,510||Open or private sale||$26.00||$169,260.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Neuralstem, Inc. operates as a biopharmaceutical company. It engages in the research, development, and commercialization of central nervous system therapies based on human neuronal stem cells and small molecule compounds. The company was founded by I. Richard Garr, Karl Y. Johe and Merrill Solomon in 1996.